4.40 USD
+0.24
5.77%
At close Dec 6, 4:00 PM EST
After hours
4.70
+0.30
6.82%
1 day
5.77%
5 days
2.09%
1 month
-23.08%
3 months
-25.80%
6 months
-37.32%
Year to date
-25.17%
1 year
-45.00%
5 years
-97.56%
10 years
-97.56%
 

About: Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).

Employees: 85

0
Funds holding %
of 6,794 funds
0
Analysts bullish %
of 11 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

85% more capital invested

Capital invested by funds: $2.53M [Q2] → $4.66M (+$2.14M) [Q3]

74% more call options, than puts

Call options by funds: $282K | Put options by funds: $162K

10.17% more ownership

Funds ownership: 5.52% [Q2] → 15.69% (+10.17%) [Q3]

46% less funds holding

Funds holding: 37 [Q2] → 20 (-17) [Q3]

71% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 24

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 13

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$23
423%
upside
Avg. target
$42
852%
upside
High target
$86
1,855%
upside

11 analyst ratings

11 positive
100%
neutral
0%
negative
0%
Benchmark
Bruce Jackson
42% 1-year accuracy
20 / 48 met price target
1,809%upside
$84
Buy
Maintained
22 Nov 2024
Canaccord Genuity
Sumant Kulkarni
32% 1-year accuracy
9 / 28 met price target
1,786%upside
$83
Buy
Maintained
14 Nov 2024
HC Wainwright & Co.
Joseph Pantginis
29% 1-year accuracy
81 / 283 met price target
605%upside
$31
Buy
Reiterated
14 Nov 2024
D. Boral Capital
Jason Kolbert
29% 1-year accuracy
24 / 84 met price target
423%upside
$23
Buy
Maintained
13 Nov 2024
EF Hutton
Jason Kolbert
29% 1-year accuracy
24 / 84 met price target
423%upside
$23
Buy
Maintained
24 Oct 2024

Financial journalist opinion

Negative
Zacks Investment Research
3 weeks ago
Clene Inc. (CLNN) Reports Q3 Loss, Misses Revenue Estimates
Clene Inc. (CLNN) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to loss of $0.40 per share a year ago.
Clene Inc. (CLNN) Reports Q3 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
2 months ago
Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules
SALT LAKE CITY, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that on September 30, 2024 it entered into a securities purchase agreement with a healthcare focused institutional investor (“Healthcare Investor”) for the issuance and sale of 742,626 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at market under Nasdaq rules. In a concurrent private placement, Clene also agreed to issue to the Healthcare Investor warrants to purchase up to 742,626 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold with one warrant to purchase one share of common stock at a combined purchase price of $4.713. The warrants have an exercise price of $4.82 per share, are immediately exercisable and will expire five years following the date of issuance.
Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules
Neutral
GlobeNewsWire
2 months ago
Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data
SALT LAKE CITY, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), announced today that it will meet in-person with the U.S. Food and Drug Administration (FDA) before the end of November 2024 to discuss CNM-Au8 development for ALS.
Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data
Neutral
GlobeNewsWire
3 months ago
Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference and host 1x1 investor meetings.
Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Positive
Zacks Investment Research
3 months ago
Wall Street Analysts Think Clene (CLNN) Could Surge 873.45%: Read This Before Placing a Bet
The consensus price target hints at an 873.5% upside potential for Clene (CLNN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think Clene (CLNN) Could Surge 873.45%: Read This Before Placing a Bet
Positive
Zacks Investment Research
3 months ago
Wall Street Analysts Believe Clene (CLNN) Could Rally 976.32%: Here's is How to Trade
The mean of analysts' price targets for Clene (CLNN) points to a 976.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Clene (CLNN) Could Rally 976.32%: Here's is How to Trade
Neutral
GlobeNewsWire
4 months ago
IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.
LOS ANGELES, Aug. 08, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.
Negative
Zacks Investment Research
4 months ago
Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates
Clene Inc. (CLNN) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.60. This compares to loss of $2.40 per share a year ago.
Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
4 months ago
Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights
SALT LAKE CITY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its second quarter 2024 financial results and provided recent updates on its CNM-Au8® programs.
Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights
Neutral
GlobeNewsWire
4 months ago
Clene to Present at the Emerging Growth Conference
SALT LAKE CITY, July 12, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference.
Clene to Present at the Emerging Growth Conference
Charts implemented using Lightweight Charts™